Xeris Biopharma Holdings, Inc. (XERS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Xeris Biopharma Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Xeris Biopharma Holdings, Inc. (XERS) has returned -26.11% so far this year and 5.65% over the past 12 months.

Based on dividend-adjusted daily data since Jun 21, 2018, XERS's average daily return is +0.07%, while the average monthly return is +1.13%. At this rate, your investment would double in approximately 5.1 years.

Historically, 51% of months were positive and 49% were negative. The best month was May 2020 with a return of +90.4%, while the worst month was Jun 2020 at -48.3%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 4 months.

On a daily basis, XERS closed higher 46% of trading days. The best single day was May 16, 2022 with a return of +29.2%, while the worst single day was Jun 25, 2020 at -48.8%.

Xeris Biopharma Holdings, Inc. has an annualized alpha of -2.92%, beta of 1.48, and R² of 0.13 versus S&P 500 Index. Calculated based on daily prices since June 22, 2018.

• This stock participated in 131.72% of S&P 500 Index downside but only 31.98% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.13 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

XERS ranks 43 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Xeris Biopharma Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Xeris Biopharma Holdings, Inc. was 96.22%, occurring on Jan 5, 2023. The portfolio has not yet recovered.

The current Xeris Biopharma Holdings, Inc. drawdown is 78.70%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Xeris Biopharma Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Xeris Biopharma Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.